Market closedNon-fractional
Seres Therapeutics/MCRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Seres Therapeutics
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Ticker
MCRB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
233
Website
www.serestherapeutics.com
MCRB Metrics
BasicAdvanced
$206M
Market cap
-
P/E ratio
-$0.62
EPS
2.14
Beta
-
Dividend rate
Price and volume
Market cap
$206M
Beta
2.14
Financial strength
Current ratio
1.677
Quick ratio
1.204
Long term debt to equity
-343.751
Total debt to equity
-358.537
Interest coverage (TTM)
-4.85%
Management effectiveness
Return on assets (TTM)
-15.74%
Return on equity (TTM)
153.67%
Valuation
Price to revenue (TTM)
1.427
Price to book
-3.46
Price to tangible book (TTM)
-3.46
Price to free cash flow (TTM)
-2.263
Growth
Revenue change (TTM)
2,380.87%
Earnings per share change (TTM)
-72.59%
3-year revenue growth (CAGR)
60.39%
3-year earnings per share growth (CAGR)
-20.34%
What the Analysts think about MCRB
Analyst Ratings
Majority rating from 7 analysts.
MCRB Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$40M
-2.67%
Profit margin
0.00%
NaN%
MCRB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.36
-$0.37
-$0.32
-$0.27
-
Expected
$0.53
-$0.50
-$0.50
-$0.34
-$0.28
Surprise
-32.57%
-26.21%
-35.63%
-20.78%
-
MCRB News
AllArticlesVideos
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
PRNewsWire·2 months ago
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Seres Therapeutics stock?
Seres Therapeutics (MCRB) has a market cap of $206M as of July 27, 2024.
What is the P/E ratio for Seres Therapeutics stock?
The price to earnings (P/E) ratio for Seres Therapeutics (MCRB) stock is 0 as of July 27, 2024.
Does Seres Therapeutics stock pay dividends?
No, Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Seres Therapeutics dividend payment date?
Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Seres Therapeutics?
Seres Therapeutics (MCRB) has a beta rating of 2.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Seres Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.